{
    "title": "TetraCopper Tetroxide",
    "inventor_name": "Marvin Antelman",
    "publication_year": 2004,
    "device_name": "TetraCopper Tetroxide (TCTO)",
    "goal": "Provide antimicrobial, antifungal, antiviral, and broader therapeutic activity against pathogens and disease conditions.",
    "problem_addressed": "Pathogenic microorganisms (bacteria, fungi, viruses, parasites) and related diseases; need for effective, non-staining, light-stable disinfectants and pharmaceuticals.",
    "concept_summary": "The invention discloses electron-active multivalent metal-oxide compounds-particularly tetra-copper tetroxide (Cu(I)_2Cu(III)_2O_4)-as pharmaceutical or disinfectant agents. The compounds contain at least two polyvalent cations with differing oxidation states, giving them a redox potential (EMF >= +0.1 V) that enables pathogen killing. The patent describes preparation methods (copper(I) oxide + caustic base + persulfate, heated) and therapeutic use (topical, parenteral, transdermal) at concentrations from 1 ppm to 500 000 ppm, optionally with oxidizing agents to enhance efficacy.",
    "detailed_description": null,
    "category": "Medical & Dental Technologies",
    "principles": [
        "Electron-transfer redox activity of multivalent metal oxides",
        "Oxidative activation by persulfate (peroxy acid salt)",
        "Polyvalent cation synergy (different oxidation states)",
        "Dose-dependent antimicrobial efficacy"
    ],
    "scientific_domains": [
        "Chemistry",
        "Materials Science",
        "Microbiology",
        "Pharmacology"
    ],
    "mechanisms_of_action": [
        "Redox-mediated disruption of microbial cell membranes",
        "Generation of reactive oxygen species via persulfate activation",
        "Metal-ion toxicity to pathogens"
    ],
    "materials": [
        "Copper(I) oxide (Cu_2O)",
        "Copper(III) oxide (Cu_2O_3) - generated in situ",
        "Persulfate (e.g., sodium persulfate)",
        "Hydroxide salts (e.g., NaOH, KOH)",
        "Water"
    ],
    "energy_sources": [],
    "inputs": [
        "Copper(I) oxide",
        "Caustic base (hydroxide)",
        "Peroxy acid salt (persulfate)",
        "Heat (to drive reaction)",
        "Water"
    ],
    "outputs": [
        "Tetra-copper tetroxide (Cu(I)_2Cu(III)_2O_4) powder or granules",
        "Antimicrobial activity against bacteria, fungi, viruses, parasites"
    ],
    "claimed_performance": "Antimicrobial efficacy of >=20 % (up to >=80 %) at ~100 ppm after 10 min contact; pathogen killing demonstrated at concentrations as low as 0.3 ppm for related silver tetroxide compositions.",
    "experimental_evidence": "The patent text cites in-vitro studies for tetrasilver tetroxide (0.3 ppm, 10 min) but provides no quantitative data for tetracopper tetroxide; efficacy is asserted rather than experimentally demonstrated.",
    "replication_status": null,
    "keywords": [
        "tetracopper tetroxide",
        "electron-active compound",
        "multivalent metal oxide",
        "antimicrobial",
        "pharmaceutical composition",
        "persulfate activation",
        "redox potential"
    ],
    "related_technologies": [
        "Tetrasilver tetroxide (Ag_4O_4) antimicrobial formulations",
        "Silver-based disinfectants",
        "Metal-oxide based water treatment",
        "Persulfate-enhanced oxidation processes"
    ],
    "controversy_level": "low",
    "confidence_score": 0.94,
    "practicability_score": 0.71,
    "fringe_score": 0.18,
    "evidence_strength": 0.32,
    "risk_score": 0.48,
    "trl_estimate": 4,
    "source_urls": [
        "https://rexresearch.com"
    ],
    "organizations": [
        "Marvin Antelman"
    ],
    "applications": [
        "Topical antimicrobial creams",
        "Water disinfection",
        "Pharmaceutical treatment of infections",
        "Surface sanitization"
    ],
    "limitations": [
        "No published in-vivo or clinical data for TCTO",
        "Potential copper toxicity and hepatomegaly at high doses",
        "Requirement for oxidizing agent to achieve full efficacy",
        "Stability and formulation challenges"
    ],
    "open_questions": [
        "What is the safety profile of tetracopper tetroxide in humans?",
        "How does efficacy compare to standard antibiotics or silver-based agents?",
        "What are the optimal dosing regimens for different routes of administration?",
        "Can the compound be scaled up cost-effectively for commercial water-treatment?"
    ],
    "red_flags": [
        "Efficacy claims lack peer-reviewed experimental data",
        "Potential for liver enlargement (hepatomegaly) noted in related silver studies",
        "Broad therapeutic claims without clinical validation"
    ],
    "evidence_quotes": [
        "TetraCopper Tetroxide ( TCTO ) is only slightly less potent vs pathogens than TetraSilver Tetroxide ( TSTO ).",
        "In a preferred embodiment, the at least one compound has antimicrobial efficacy, preferably of at least about 20% ... at least about 80% ... about 100 ppm of the at least one compound is placed in contact for about 10 minutes with microbes having a cell density of approximately 75,000 CFU/mL.",
        "The invention also relates to a method for preparing tetracopper tetroxide, which includes: combining a copper(I)-containing compound and a caustic solution to form a reactant solution; and heating the reactant solution to a temperature and for a time sufficient to produce a detectable amount of the tetracopper tetroxide compound."
    ]
}